Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
Tonix presented a combined analysis of the Phase 3 RELIEF and RESILIENT studies at the IASP 2026 World Congress on Pain showing TONMYA improved FIQR Symptoms and Function scores versus placebo in fibromyalgia patients. Both domains reached statistical significance at Week 14 in RESILIENT (p≤0.001) and nominal significance in RELIEF (p<0.01), with no new safety signals observed.
Key figures
- Drug Name
- TONMYA (cyclobenzaprine HCl sublingual tablets)
- Phase Of Trial
- Phase 3
- P Value Relief
- p<0.01 (nominal significance, Week 14)
- P Value Resilient
- p≤0.001 (Week 14, both FIQR domains)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.